H.C. Wainwright Reiterates Neutral Rating on Alkermes (ALKS)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Weakness in this biotech stock is a buying opportunity: Mizuho
July 31, 2026 9:00 AM EDTMizuho reiterated an Outperform rating and $65 price target on a key biotech stock in a note on Friday, telling investors that a selloff following the drugmaker's second-quarter results is a buying opportunity.
Analyst Uy Ear said Alkermes (NASDAQ: ALKS) posted a solid quarter, with product sales, manufacturing and royalty revenues broadly in line with estimates... More
